

REMARKS

Currently Claims 1-96 are pending. Claims 23-33, 70-82, 84-89, and 91-96 have been cancelled without prejudice. Claims 1, 3, 4, 6, 7, 9-14, 16, 18, 19, 21, 34, 37, 38, 40-42, 44, 46-49, 51-54, 56, 58, 60, 63-67, 69, 83, and 90 have been amended to place them in form appropriate to US practice and/or to reduce the filing fee by removing multiple dependencies.

The specification has been amended to include a reference to related applications/claim of priority to the corresponding PCT application and foreign filed application.


Applicants have attached an Abstract on a separate sheet of paper as required by US practice.

Applicants respectfully submit that the present application is in condition for examination and respectfully request the early consideration thereof and the issuance of a Notice of Allowance forthwith.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Date: August 3, 2006
GlaxoSmithKline Inc.
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Tel. (919) 483-9024
Fax: (919) 483-7988

Respectfully submitted:


J. Michael Strickland
Attorney for Applicants
Reg. No. 47,115